Integral Diagnostics Limited (ASX: IDX) — Stock Profile

About IDX (ASX: IDX)

Integral Diagnostics Limited operates as a healthcare services provider, delivering diagnostic imaging to general practitioners, medical specialists and allied health professionals, along with their patients, across Australia and New Zealand. Its service offering spans magnetic resonance imaging, positron emission tomography, computed tomography, mammography, interventional radiology, ultrasound and radiography including x-ray and EOS imaging, making it a broad-based provider covering most major diagnostic imaging modalities used in referral-based clinical practice.

The group's imaging network gives referring clinicians access to both routine and advanced procedures, from standard radiography and ultrasound through to higher-end modalities such as MRI and PET, along with EOS low-dose imaging and interventional radiology services that support more complex diagnostic and procedural needs. Integral Diagnostics was founded in 1967 and today operates as an established participant in the Australian and New Zealand diagnostic imaging sector, with its head office located in Melbourne, Australia.

MFAM Research

No mfam research yet.

Latest Announcements

  • Integral Diagnostics (ASX: IDX) – FY26 Full Year Investor Presentation
    August 25, 2026
    Integral Diagnostics delivered a strong FY26 result with revenue climbing 25.6% to $788.7 million, demonstrating the material contribution from its Capitol Health merger completed in December 2024. Operating EBITDA reached $164.8 million with margin expansion to 20.9%, up 80 basis points year-on-year and tracking to management’s guidance. The result reflects both organic growth momentum and […]
  • Integral Diagnostics (ASX: IDX) – Integral Diagnostics FY26 Full Year Results
    August 25, 2026
    Integral Diagnostics Limited delivered a strong FY26 result with operating net profit after tax surging 50.1% to $47.4 million, significantly outpacing underlying revenue growth of 25.6% to $788.7 million. This substantial earnings leverage reflects disciplined operational execution and the full-year contribution of Capitol Health, which was acquired on 20 December 2024, positioning the company to […]
  • Integral Diagnostics (ASX: IDX) – Integral Diagnostics Files FY26 Annual Report
    August 25, 2026
    Integral Diagnostics has reported a substantial earnings turnaround in FY26, with net profit surging 677 percent to $22.0 million from $2.8 million in the prior year. This dramatic improvement reflects both operational leverage and a return to profitability at scale, signaling that the imaging diagnostics operator has successfully navigated a challenging period and is now […]
  • Integral Diagnostics (ASX: IDX) – FY26 Results and New CFO Appointment
    August 10, 2026
    Integral Diagnostics’ preliminary FY26 results demonstrate substantial operational momentum, with revenue expected to reach between $788 million and $790 million, representing growth of approximately 25 percent compared to the prior corresponding period. This expansion reflects a full 12-month contribution from the Capitol Health acquisition, which delivered only around six months of earnings in the prior […]
  • IDX (ASX: IDX) – New Chief Executive and Managing Director Appointment
    August 6, 2026
    Integral Diagnostics Limited (ASX: IDX) has formally commenced the tenure of Jason Martinez as Managing Director and Chief Executive Officer on 6 August 2026, following the completion of his obligations to his previous employer. The appointment, which was announced to the market on 10 November 2025, represents a significant leadership transition for the diagnostic imaging […]

Financial Summary

Price History

Same Industry — HealthcareSame Sub-Industry — Diagnostics & Research
Share This